Physician profile
Lee A Compton
NPI 1184178154
$5,401.76
in general payments reported to CMS, 2019-2025
27 companies · $926 in 2025
The $926 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $327 · 2021: $310 · 2022: $989 · 2023: $853 · 2024: $1,666 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Entertainment: $15.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.35 |
| Entertainment | $15.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $881.65 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Abbvie INC. | $625.31 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $576.03 | 2019-2022 | |
| Alcon Vision LLC | $522.28 | 2020-2025 | Total30, Clareon, Eysuvis |
| Oyster Point Pharma, INC. | $429.75 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $347.23 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $282.16 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Lkc Technologies, INC. | $236.47 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $235.06 | 2022-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $222.15 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $170.77 | 2022-2023 | Tepezza |
| Amgen INC. | $138.77 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $128.49 | 2019-2021 | |
| Genentech USA, INC. | $115.05 | 2023 | Vabysmo |
| Biotissue Holdings INC. | $86.15 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $75.02 | 2019-2022 | |
| Astellas Pharma US INC | $57.80 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.78 | 2019 | |
| Eyevance Pharmaceuticals LLC | $38.58 | 2020-2022 | |
| Lombart Brothers, INC. | $37.04 | 2019 | |
| Dompe US, INC. | $31.02 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $28.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $27.50 | 2024 | Acthar |
| Optovue, INC. | $20.47 | 2021 | |
| Tearlab Corp | $19.07 | 2022 | |
| Optos, INC. | $15.54 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.